The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
about
Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate CancerSuppression of LIM and SH3 Domain Protein 1 (LASP1) Negatively Regulated by Androgen Receptor Delays Castration Resistant Prostate Cancer Progression.Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancerIn vitro and in vivo model systems used in prostate cancer research.Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy.Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.HER2 as a novel therapeutic target for cervical cancer.Targeting the glucocorticoid receptor in breast and prostate cancers.A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer.Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside.Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives.Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer.Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression.Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress.Sox5 contributes to prostate cancer metastasis and is a master regulator of TGF-β-induced epithelial mesenchymal transition through controlling Twist1 expression.Androgen receptor reverts dexamethasone‑induced inhibition of prostate cancer cell proliferation and migration.Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation.Delineation of the androgen-regulated signaling pathways in prostate cancer facilitates the development of novel therapeutic approaches.Does increased expression of glucocorticoid receptor support application of antagonists to this receptor for the treatment of castration resistant prostate cancer?
P2860
Q28067556-A32C4E15-E863-4EF2-AB86-DD4FAF2F5B3BQ30008838-D347C05B-0A5D-411A-89B3-CF4FFB19BB56Q35615320-906BF5B9-67FA-48DD-A6C3-04E1C93442FCQ35806390-52C5396C-BE35-407F-98C7-A44538DE8909Q36289505-A86A1087-70B4-4B81-827F-CEA5E3CF05CAQ36398998-1BB117EF-8513-4059-BA94-DAF01C015830Q36546614-F2DFBAA0-32FC-4FA6-8F19-4E2232DF2DEEQ36729300-0726B7EB-8161-4B33-AD89-784ED16DEE8CQ37056571-E2EC742E-1A6C-43B5-B694-FA48D608D304Q37295639-541CAABB-C56A-4CE5-80A2-78EDB09AF302Q38827723-58234D3C-DD26-47DD-8780-D5D14AC5F7E1Q39041932-C28BE512-23CE-4549-8F67-F2D032B318F2Q39285589-5982E3B8-BD96-4BFD-91D4-16DA323ACDACQ41824705-9331A6B8-6906-4140-9D05-F3FA54264BF9Q41870646-A5CFA375-F219-449B-A44E-4C5043A0394DQ46434898-5073BBD7-8D32-45EC-B97B-D69B67CA79D1Q47418660-A94F51B5-136D-4FC5-B5CB-79B708970B58Q50047876-7534A9FD-FA29-4988-B3D7-7C0B0C909CF4Q53561117-C3DBB2A9-F956-47EB-AFF3-3A8A64DEDDC1Q53699332-016D3EDE-F5F0-4139-9DC1-D67D7D0DF8FDQ56976083-5DCB4D41-C304-48CE-BFDB-6DEEBAA3D774
P2860
The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The expression of glucocortico ...... signaling in prostate tumors.
@en
type
label
The expression of glucocortico ...... signaling in prostate tumors.
@en
prefLabel
The expression of glucocortico ...... signaling in prostate tumors.
@en
P2093
P2860
P356
P1476
The expression of glucocortico ...... signaling in prostate tumors.
@en
P2093
Helen Cheng
Ladan Fazli
Liangliang Liu
Martin E Gleave
Paul Rennie
Xuesen Dong
P2860
P304
P356
10.1002/IJC.29147
P577
2014-08-27T00:00:00Z